Lavie Bio

Evogene Ltd. (NASDAQ: EVGN) (TASE:EVGN) Q3 2022 revenues were $466,000, a 208% increase in comparison to $151,000 in the same period of the previous year and were primarily due to revenues recognized per the collaboration agreement of Evogene's subsidiary AgPlenus with Corteva. Q3 2022...

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year. Revenues were primarily due to the initial sales of Lavie Bio's Thrivus product (previously branded as Result) and sales of Canonic products in...

Computational biology company Evogene Ltd. (NASDAQ: EVGN)  will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. On the day of the announcement, the company's management will host a conference call to discuss the results at 09:00 a.m. EST....